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Emergency Medicine
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Calcium Channel Blockers, and Digoxin
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Dayton, Ohio; Kayti Kintner, fourth-year pharmacy student from Sunbury, Ohio; Kelsey Fink, fifth-year pharmacy student
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education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.
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Objectives
After completion of this program, the reader should be able
to:
1. Explain the pathophysiology behind oral hypoglycemic agents, atypical antipsychotic agents, betablockers, calcium channel blockers, and digoxin.
2. Describe the presenting symptoms associated with the
aforementioned drug classes in an overdose.
3. Discuss recommended treatment options in cases of
toxicity.
4. Describe the pharmacist's role in treating toxicological
emergencies.
Abstract
The number of medication toxicities has been steadily increasing with more patients presenting to the emergency
department for both intentional and unintentional overdoses. Oral hypoglycemics, atypical antipsychotics, betablockers, calcium channel blockers and digoxin overdoses
are some of the more common medication toxicities health
care professionals may see in practice. Toxic doses of oral
hypoglycemic agents, beta-blockers, calcium channel blockers and digoxin have more definitive options for treatment,
while atypical antipsychotic overdoses are managed with
supportive care. Pharmacists in particular play a pivotal role
in identifying presenting symptoms and recommending appropriate treatment options in toxicological emergencies.
Introduction
While incidences of toxic exposure to medications may be
intentional or unintentional, trends are indicative of a rise in
medication overdoses.1 Emphasis on opioid and prescription
analgesic abuse remains a high priority. However, several
other medication classes may be overlooked. In 2004, there
were upwards of 10,000 cases of oral hypoglycemic overdose
used in the treatment of diabetes.2-3 A significant number of
atypical antipsychotic overdoses were reported from 2001 to
2005, some of which ended in fatality. 4 Beta-blockers and
calcium channel blockers show a combined incidence of over
30,000 overdoses, 57 of which were fataJ.S.19,20 The cardiac
glycoside digoxin has also been associated with severe toxic
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events and patient fatalities.6 Pharmacists, as drug experts,
should be aware of toxicity potential for all medications and
should be prepared with the knowledge for treatment.
Oral Hypoglycemics
Epidemiology
Type 2 diabetes mellitus (DM2) is a disease on the rise, affecting over 190 million patients in 2006, with a projected
population of over 325 million by 2025.3 In the attempt to
treat DM2, the use of oral hypoglycemics has steadily risen
with the disease prevalence. A variety of medication classes
are available including sulfonylureas, biguanides, meglitinides, thiazolidinediones and alpha-glucosidase inhibitors.
While such therapy choices are appropriate for controlling
blood glucose levels in the insulin-resistant patient, several
of these classes have been shown to reach toxic levels,
thereby causing severe adverse effects. Biguanides, for example, accounted for 40 percent of the 10,000+ cases, as did
sulfonylureas; a majority of which were seen in children.2.3
Mechanism
As there are several classes of oral hypoglycemics, it is important to make distinctions by which their mechanisms
work so that toxic levels can be more readily identified and
treated. Sulfonylureas work by lowering potassium channel
permeability in pancreatic beta cells, leading to release of
intracellular calcium and release of insulin-containing granules. The result is a lowered threshold at which insulin will
be secreted in the presence of glucose.7 It should be noted
that the second generation sulfonylureas, including glyburide, glipizide, and glimepiride, have a shorter half-life
(t1;2) and duration of action (DOA).2 Meglitinides work similarly in lowering the potassium channel permeability allowing for intracellular calcium to depolarize pancreatic beta
cells.s By stimulating the Peroxisome Proliferator Activated
Receptor-gamma (PPAR-gamma) in adipose, skeletal muscle,
and liver tissue, thiazolidinediones promote the expression
of glucose controlling genes in the presence of insulin. 9 In
order to increase insulin sensitivity, biguanides will increase
the ability to metabolize glucose, and decrease glycogenolysis, the breakdown of glycogen to form glucose.10 Alphaglucosidase inhibitors will slow the enzymatic breakdown of
carbohydrates, thereby lowering the rise in post-prandial
blood glucose levels. By this process, glycosylated hemoglobin will be decreased. 11 ln recognizing the basic mechanisms
for the varying classes of oral hypoglycemics, identifying appropriate treatment becomes more clear.
Presenting Symptoms of Toxicity
Upon over-ingestion of oral hypoglycemics, patients will tend
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to have similar presentations, yet the specific drug class will
be distinguishable upon the presence of unique symptoms.
As could be expected, patient presentation is associated with
a hyperinsulinemic/hypoglycemic state. In sulfonylurea toxicity, for example, it is common to see neuroglycopenia
(glucose deficiency in the brain), coma and seizures, all associated with low glucose levels. Additionally, counterregulatory hormone effects in response to the low glucose
may induce diaphoresis and tachycardia.3,7 An acute state
may occur in as little as one to eight hours, where a chronic
toxicity may be delayed over several days.3 Meglitinides will
present similarly to sulfonylureas, however, they are associated with a quicker onset of action (30 minutes versus one to
eight hours) in an acute situation.3
Patients with increased levels of thiazolidinediones will
show no acute symptoms of toxicity, as they are dependent
on the presence of insulin to exert their effects. In a chronic
overdose, there would be an elevation of transaminases as
well as alkaline phosphatase levels, indicating hepatic toxicity. Also associated with thiazolidinediones is an increased
prothrombin time (PT) and international normalized ratio
(INR), in addition to the expected hypoglycemic sequelae
such as bradycardia, coma and hypotension.3
Biguanides are unique in that they have the potential to
cause lactic acidosis. It is common for patients with overdoses (or even as side effects in normal doses) to present
with gastrointestinal (GI) discomfort, abdominal pain, nausea, vomiting and diarrhea. Alongside tachypnea, hypotension, hypothermia and confusion (commonly associated with
hypoglycemia), it is possible to see renal failure and cardiovascular effects such as ventricular arrhythmias and vascular
resistance with biguanides.3
Diagnosis and Treatment
While no single test may be used to diagnose a patient presenting with oral hypoglycemic toxicity, a combination of
subjective and objective information may be used to assess
an individual's status. There are many common presenting
symptoms such as hypoglycemia, and some distinct tests that
set drug classes apart. For example, liver function tests may
be appropriate for suspected thiazolidinedione toxicity, or
arterial blood gas levels in the instance of biguanides. Timeline may also be a factor in determining the class of drug,
whether the onset was acute such as with some sulfonyIureas, or chronic, which is more commonly associated with
thiazolidinediones.
In treating the sulfonylurea and meglitinide classes, it is
important to first give the patient quickly metabolized carbohydrates in the form of oral glucose or intravenous (IV)
dextrose. A SO mL bolus of SO percent dextrose (DSOW) and
dextrose containing IV fluids should be administered.3.12,13
The possibility for recurrent hypoglycemia exists in which
the pancreas will release insulin in response to the IV dextrose. Upon refractory hypoglycemia, use of alternative therapy is required.13 The second option for sulfonylureainduced hypoglycemia is octreotide, a somatostatin analog
that inhibits glucagon and insulin secretion.14 By binding to
June 2014 Volume 5, Issue 2

somatostatin-2 receptors on pancreatic beta cells, it inhibits
G-protein coupled voltage gated calcium channels from being
opened. This inhibition of calcium influx will stop further
insulin release by pancreatic beta cells.13 Octreotide is U.S.
Food and Drug Administration (FDA) approved for the treatment of various endocrine related disease states such as acromegaly and pancreatic tumors; however, it has not been
FDA approved as an antidote for sulfonylurea toxicity.13,14
Subcutaneous and intravenous routes of administration have
equivalent bioavailability with peak effects occurring after
30 minutes. Adult dosing of octreotide ranges from SO to
100 mcg subcutaneously every six to 12 hours, while pediatric dosing requires 1 to 2 mcg/kg up to SO mcg every six to
12 hours.13 Glucagon may also be used for the treatment of
sulfonylurea overdose, as it will promote the breakdown of
glycogen and synthesis of glucose to combat low glucose levels.13 Glucagon, however, may also influence the release of
insulin.13 Studies were not found to provide evidence of glucagon or octreotide as effective treatment options in meglitinide overdose. Activated charcoal will bind to meglitinide
entities and is most effective early on in treatment.3
In the instance of lactic acidosis with excess biguanide
ingestion, the primary goal in treating the patient is acidbase restoration, which can be achieved with the use of sodium bicarbonate (1-2 mEq/kg). Activated charcoal may be
administered to the patient, even late in an overdose, as
biguanides will still be present in the gastrointestinal tract.
In an emergency situation where renal function is critically
impaired, hemodialysis may be initiated alongside sodium
bicarbonate.3
Thiazolidinediones, which are known to cause hepatic toxicity, are most appropriately treated with drug discontinuation.3 Neither pioglitazone or rosiglitazone were found to be
dialyzable through either conventional (coefficient of ultrafiltration <8 mL/hour/mm), high permeability (coefficient of
ultrafiltration >8 mL/hour/mm) or peritoneal dialysis.ls
Atypical Antipsychotics
Epidemiology
Atypical antipsychotic medications, including clozapine,
risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole, have become widely popular in treating schizophrenia and related psychiatric disorders. These drugs have a
more favorable adverse effect profile compared to the traditional antipsychotics, contributing to their preference over
other medications. However, overdose of antipsychotic medications is common, and in rare cases even fatal. From 2001 to
200S, 1S6,431 ingestions were reported to the Toxic Exposure Surveillance System (TESS), an organization maintained
by the American Association of Poison Control Centers.4 Of
the 1S6,431 cases reported, 8,894 had major effect outcomes
and 403 resulted in death.4 Total fatalities to date due to
atypical antipsychotic drug overdose are unknown.
Mechanism
Atypical antipsychotic medications are tricyclic dibenzothiazepines that have unique receptor binding affinities and
more favorable side effect profiles. The atypical agents are
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defined clinically as having minimal or no extrapyramidal
symptoms at appropriate therapeutic doses and have less
potential to cause tardive dyskinesias and elevation of serum
prolactin concentrations.4,16 Atypical antipsychotics are dopamine D2 receptor antagonists and serotonin 5HT2A receptor antagonists. The decreased incidence of extrapyramidal
side effects is attributed to the decreased affinity of the atypical antipsychotics to the Dz receptor. The "negative" symptoms of schizophrenia, including avolition, anhedonia, alogia
and social withdrawal, are alleviated due to the drugs' 5HTZA
antagonistic activity.4.16 However, aripiprazole differs from
other atypical antipsychotics because it is a partial agonist at
the Dz and 5HT1A receptors and an antagonist at the 5HT2A
receptors.4Typical side effects that would be expected of
these drugs include orthostatic hypotension due to aadrenergic receptor blockage, sedation, sinus tachycardia
and urinary retention (associated with clozapine, olanzapine,
quetiapine).16
Presenting Symptoms of Toxicity
Toxic doses in patients are highly variable because an overdose may occur at therapeutic or supratherapeutic doses.
The most serious presenting symptoms involve the central
nervous system (CNS) and cardiovascular system. A patient
may present with pronounced sedation, most common with
clozapine and quetiapine, due to blockade of CNS histamine
Hi receptors. Tachycardia, mild hypotension and QT prolongation may also be present. Another serious and potentially
fatal symptom of overdose is neuroleptic malignant syndrome (NMS) which is characterized by hyperthermia, autonomic instability, neuromuscular rigidity and altered mental
status.16 Patients will most likely seem agitated, have muscular rigidity and may present with additional extrapyramidal
effects such as bradykinesia and tremor. 16 Lastly, antimuscarinic delirium may also be present in toxicity due to antagonism of central and peripheral muscarinic receptors.
Antimuscarinic delirium is most commonly seen with clozapine, olanzapine and quetiapine, and less often seen with
risperidone, ziprasidone and aripiprazole. Presenting symptoms of antimuscarinic delirium that may suggest overdose
include: hyperthermia, tachycardia, blurred vision, flushed
dry skin, absent bowel sounds, urinary retention, agitation,
hallucinations, mumbling speech and repetitive picking behavior.16

acid and lithium.17 Co-ingestion of nonprescription analgesics such as acetaminophen and aspirin are also common.
Obtaining a serum concentration of acetaminophen and salicylates should be considered in all toxic cases.16,17
Supportive therapy is the cornerstone of treatment for
patients with antipsychotic overdose. Use of supplemental
oxygen in hypoxic cases and administration of thiamine and
parenteral dextrose in altered mental status patients are
typical first-line therapies in managing overdoses. All
patients who are symptomatic should be continuously
monitored for cardiac abnormalities and have an electrocardiogram (ECG), particularly focusing on QT prolongation.
Moreover, serum electrolytes should be monitored and corrected, as hypokalemia and hypomagnesemia could exacerbate QT dysrhythmias. Hypotension due to peripheral alpha
1-blockage can be corrected using intravenous fluids. If
required, vasopressors of choice include alpha-agonists,
norepinephrine or phenylephrine.16
Gastrointestinal decontamination procedures are rarely necessary with antipsychotic overdoses. Activated charcoal (1 g/
kg by mouth or nasogastric tube) can be considered in a
large or multi-drug overdose within an hour of ingestion as
long as the patient does not present with sedation or vomiting.16,17While the administration of activated charcoal is time
sensitive, the antimuscarinic effects and slowed gastric emptying caused by the antipsychotic may improve the beneficial
effects of activated charcoal.
Pronounced anticholinergic symptoms are common with
atypical antipsychotics. The cholinesterase inhibitor physostigmine has been used successfully in overdosed patients,
particularly in improving agitated delirium. Physostigmine
should be given in 0.5 mg increments every three to five minutes under close patient observation.17 Other cholinesterase
inhibitors such as edrophonium, neostigmine and pyridostigmine should not be used to improve anticholinergic delirium
because these drugs do not cross the blood-brain barrier.17

Diagnosis and Treatment
Diagnosing an overdose caused by atypical antipsychotics is
primarily supported by gathering information in the patient's
clinical history, physical examination and presenting
symptoms. Obtaining serum concentrations of antipsychotics
is not helpful in guiding therapy because data listing toxic
serum concentrations are not widely available and the concentrations are not definitively correlated with clinical signs
and symptoms.17 Routine urine screens of commonly abused
drugs do not detect antipsychotics and therefore are not
helpful in managing toxic cases. 16

Beta-Blockers and Calcium Channel Blockers
Epidemiology
Beta-blockers (BB) and calcium channel blockers (CCB) are
used to treat various medical conditions such as hypertension, angina pectoris, supraventricular tachycardias, tremors,
anxiety and others. According to the American Association of
Poison Control's 2007 records, 10,084 exposures to CCBs
were reported, of which 435 were classified as moderate to
major toxicity and 17 exposures resulted in death.18 The National Poison Data System (NPDS) reported nearly 20,000
exposures to BBs in 2007, of which 200 to 400 cases were
classified as major toxic events with over 40 deaths.10,19 Interestingly, propranolol accounts for a majority of selfinduced poisonings, which may be attributed to its use in
treating anxiety, stress and migraine patients.

Co-ingestion of other medications is common in overdose,
especially with other psychotropic agents such as antidepressants, sedatives, hypnotics, anticholinergics, valproic

Mechanism
Although BBs and CCBs have differing mechanisms of action,
both are involved in interfering with calcium flux across cell
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membranes. Cardiovascular function is dependent on calcium flow across cell membranes to regulate cardiac automaticity, myocardial conduction and contraction, vascular
tone and insulin secretion.
Beta-blockers selectively antagonize 13-adrenergic receptors
that are linked to Gs proteins. Three subtypes of the
13-receptor are known: 131-receptors regulate myocardial tissue and effect rate of contraction, 132-receptors regulate
smooth muscle tone and influence vascular and bronchiolar
relaxation and 133-receptors are thought to effect lipolysis
with some influence on cardiac inotropy.20 Under normal
conditions, these Gs proteins stimulate the increase of
intracellular cyclic adenosine monophosphate (cAMP) with
subsequent increase of calcium flow through L-type calcium
channels and release of calcium from the sarcoplasmic reticulum. The increase in intracellular calcium is directly proportional to the overall strength of contraction brought on by
the interaction between actin and myosin. Beta-blockers
competitively inhibit 13-receptors, therefore indirectly decreasing cAMP production and intracellular calcium levels.
This mechanism results in decreased cardiac automaticity,
slowed conduction and decreased contractility. 20 Over 15
BBs are on the market today, many of which have variable
selectivity for 13-receptor subtypes and fewer which have areceptor antagonistic activity, also referred to as intrinsic
sympathomimetic activity. Other properties of individual BBs
that are important to note in toxic cases are the lipid solubility and sodium channel blocking activity.2 1 Highly lipophilic
agents, such as propranolol, can cross the blood-brain barrier resulting in CNS effects.
Calcium channel blockers have the same overall pharmacological result as beta-blockers with a slight difference in
mechanism. CCBs directly inhibit calcium influx by blocking
voltage-gated L-type calcium channels located in myocardial
cells, smooth muscle cells and 13-islet cells of the pancreas.
Two types of CCBs are known and exhibit different selectivity for cardiac versus vascular channels. The dihydropyridine
(DHP) CCBs, which include amlodipine and nifedipine,
preferentially act on peripheral vasculature. Antagonism of
calcium channels in the peripheral vasculature results in decreased coronary vascular resistance, increase in coronary
blood flow and overall vasodilation. Verapamil and diltiazem
make up the non-dihydropyridine (Non-DHP) CCBs that are
somewhat less selective and target both cardiac tissue and
peripheral vasculature. The results of the nondihydropyridines acting in cardiac tissue include decreased
nodal conduction and decreased myocardial contractility.
Moreover, decreased insulin secretion is an outcome of CCB
activity in the pancreas.
Presenting Symptoms of Toxicity
Patients experiencing toxic doses of either BBs or CCBs may
present with symptoms within two to three hours of ingestion. Immediate-release preparations develop toxicity within
six hours and toxicity from sustained-released products may
be delayed for six to 12 hours.1s,19 In general, toxicities usually present as an extension of the drug's therapeutic effects.
Specifically, bradycardia and hypotension caused by myocarJune 2014 Volume 5, Issue 2

dial depression and peripheral vasodilation are expected.20
Early or mild symptoms may include dizziness, fatigue and
lightheadedness that may manifest as lethargy and altered
mental status. Common ECG findings during BB toxicities are
first-degree atrioventricular (AV) block and interventricular
conduction delays; ECG findings for CCB toxicities are sinus
bradycardia, AV blocks, complete heart block, junctional
rhythm and QT prolongations.19,20
While the clinical manifestations for BB and CCB overdose
are similar, there are subtle differences that may suggest
poisoning in one class over the other. Hyperglycemia is expected to present more with CCBs, particularly with serious
verapamil, diltiazem and DHP overdoses, whereas hypoglycemia is common in BB toxicity.20 Mild hypokalemia and hypocalcemia have been reported in CCB overdose, but are not
reliable differentiating factors. CCB toxicity can lead to hypoperfusion and end-organ ischemic complications such as
non-cardiogenic pulmonary edema, seizures, myocardial infarction and renal failure.20 Beta-blocker toxicities can also
have dangerous complications such as rhabdomyolysis, renal
failure, seizures and bowel infarction.19
Diagnosis and Treatment
Diagnosing toxicities due to BBs and CCBs is primarily supported by clinical manifestations, continuous cardiac monitoring with an ECG and serum glucose concentrations. While
obtaining serum glucose concentrations is not definitively
diagnostic, this value may warrant further treatment. In reported cases, patients who required vasopressors, a pacemaker or who died of overdose had an initial mean serum
glucose concentration of 188 mg/dL compared to an average
of 122 mg/dL in those not requiring intervention.1B,19These
findings may be useful in determining the initial severity of
toxicity.
Managing BB and CCB overdoses can be accomplished in a
similar manner, as their mechanisms are physiologically
comparable. Pharmacological therapies will be discussed in
further detail in the following paragraphs. When toxicity is
suspected through clinical manifestations, an ECG should be
obtained and repeated every one to two hours, along with
attention to airway, breathing and circulation. Supplement
oxygen as clinically necessary and obtain intravenous access.rn-20 Initial resuscitation fluid bolus with 10 to 20 mL/kg
of intravenous crystalloids, likely normal saline, is recommended for hypotensive patients, however be aware that
poisoning may produce drug-induced inotropic failure, making fluid overload a concern.1s-20 Gastrointestinal decontamination is recommended to prevent delayed cardiovascular
toxicity, especially with CCBs. Multiple-dose activated charcoal (MDAC) is recommended ideally within one hour of ingestion at an initial dose of 1 g/kg followed by 0.5 g/kg if the
patient shows signs of continuing absorption. Whole-bowel
irrigation (WBI) should be used in the presence of suspected
overdose with sustained-release CCBs. Whole-bowel irrigation with polyethylene glycol solution at 1 to 2 L/h orally or
via nasogastric tube is recommended and should be continued until the rectal effluent is clear.rn
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Pharmacological Treatments

Atropine
Atropine is an initial treatment of choice to be administered
in patients with symptomatic bradycardia. Although atropine
was ineffective in improving heart rate in clinical cases of
CCB overdoses, atropine should still be considered based on
its availability and familiarity. Doses can be administered at
0.5 to 1 mg IV every two or three minutes up to a maximum
dose of 3 mg.10 In severely poisoned patients, treatment failure with atropine is expected, however initial treatment with
calcium may improve the efficacy of atropine.
Catecholamines
Catecholamines are administered to act as agonists at ~1adrenergic receptors in the myocardium or at a1-adrenergic
receptors in the peripheral vascular smooth muscle in order
to improve heart rate, contractility and peripheral vasoconstriction. However, the effects of catecholamines on
~-adrenergic receptors may be blunted due to the excessive
~-receptor blockage from the drug overdose. No single agent
has been proven to be consistently effective in all clinical
cases due to the variability of the patient and involved receptors.rn Epinephrine has shown to improve heart rate and
blood pressure the most and is a reasonable choice for either
a BB or CCB overdose. Dopamine and norepinephrine are
also logical choices; especially in CCB toxicities. 18 Using a
combination of inotropes and vasopressors will most likely
be necessary.
Calcium
Calcium is a logical treatment option for BB and CCB toxicity
with the intention of increasing extracellular calcium,
allowing calcium influx through unblocked L-type channels.
Calcium ions can correct the negative inotropy, delayed conduction, and hypotension in poisoned patients, but have a
limited effect on heart rate. 2 0 Ideal doses of calcium are not
yet established, but the attention and selection of a specific
calcium salt is critical for dosing. Calcium chloride contains
three times the amount of elemental calcium as calcium gluconate and is therefore preferred, although there is no difference in efficacy.10-20 Literature suggests initial intravenous
infusion of approximately 13 to 25 mEq of calcium over five
minutes, which equates to 10 to 20 mL of 10 percent calcium
chloride or 30 to 60 mL of 10 percent calcium gluconate. The
initial infusion can be followed by either repeat boluses
every 15 to 20 minutes up to three or four doses or a continuous infusion of 0.5 mEq/kg/hr of calcium.10 It is important to note that calcium chloride has a high potential to
cause tissue damage if extravasated, therefore it is best if
administered through a central venous catheter.20
Glucagon
Glucagon is the therapy of choice in BB overdose because it
has both inotropic and chronotropic effects independent of
activating ~-adrenergic receptors. Ideal doses of glucagon are
not yet established and maximum doses are undefined. An
appropriate starting dose is a bolus of 5 to 10 mg (150 mcg/
kg) over one to two minutes followed by a continuous infusion of 2 to 10 mg/hour once a response occurs.20 The glucagon infusion could also be started at the "response dose,"

B

which means the hourly infusion rate is set equal to the initial cumulative dose required to obtain a response. Because
nausea and vomiting can occur with bolus doses of glucagon
over 50 mcg/kg, airway protection is necessary to prevent
aspiration. 19 Hyperglycemia and mild hypocalcemia can also
be expected and should be treated appropriately.

Hyperinsulinemia Euglycemia
Hyperinsulinemia euglycemia (HIE) therapy has become particularly more prominent in the treatment of CCB toxicity,
but is also clinically used in BB overdose.19 Insulin facilitating
myocardial utilization of carbohydrates is the foundation for
the theory behind using insulin in treating BB and CCB overdose. Under healthy conditions, myocardial tissue relies on
free fatty acids to fuel its metabolic needs. Drug poisoning
shifts its need to be more carbohydrate dependent.22 Toxic
levels of BBs and CCBs also inhibit calcium-mediated insulin
secretion from the ~-islet cells in the pancreas, therefore
myocardial cells become dependent upon concentration gradients for glucose uptake rather than insulin-mediated active
transport.20,22 Studies involving verapamil toxicity showed
improved glucose uptake with insulin administration and
consequently improved contractility. Again, ideal doses have
not been established but typical therapy begins with a bolus
of 1 unit/kg of regular human insulin with 25 to 50 mL of
DSOW IV, followed by insulin infusion 1 units/kg/hr and dextrose infusion at 0.5 g/kg/hr. 20.22 Glucose should be monitored every 30 minutes for the first four hours and titrated to
maintain euglycemia. A response to HIE therapy may be delayed for 15 to 60 minutes. It is also important to monitor
glucose and electrolyte levels for several hours after insulin
is discontinued.
Phosphodiesterase Inhibitors
Phosphodiesterase inhibitors (PD!s) such as amrinone and
milrinone are typically used as second-line agents in BB and
CCB toxicity. Phosphodiesterase inhibitors inhibit the breakdown of cAMP by phosphodiesterase, thereby increasing
cAMP concentrations, increasing intracellular calcium and
improving inotropy. Case reports suggest an initial bolus
dose of 1 mg/kg of amrinone over Z minutes followed by a
continuous infusion of 5 to 20 mg/kg/min.10
Phosphodiesterase inhibitors have been clinically successful
when used in combination with another inotrope, such as
glucagon.10 Glucagon ·stimulates cAMP production while POis
inhibit its breakdown, increasing the overall effects of cAMP.
However, PDis nonselectively inhibit phosphodiesterase in
the vascular smooth muscle, causing smooth muscle relaxation, peripheral vasodilation and hypotension. The nonselective behavior of PD!s makes it a second-line agent and should
only be used in patients who have hemodynamic monitoring,
as the additive hypotension could be dangerous in BB and
CCB poisoning.10,20

Methylene Blue
Methylene blue (MB) is an experimental antidote for refractory vasodilatory shock from dihydropyridine overdoses,
particularly amlodipine. Methylene blue is thought to interfere with guanylate cyclase activity and endothelial nitric
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oxide synthase activity, preventing the cGMP production and
vasodilation effects of amlodipine.23,2 4 Literature that
supports the use of MB in refractory vasodilatory shock is
limited to retrospective case reports.23 Patients in two case
reports were administered MB 14 and 16 hours post ingestion. They received 2 mg/kg IV of MB over 20 minutes followed by 1 mg/kg/hr after not responding to normal saline,
calcium gluconate, glucagon, dopamine, norepinephrine and
high-dose insulin euglycemia therapy.23,2 4 One hour after MB
administration, the case patients responded with an elevation in blood pressure and heart rate.23. 24 Clinically, methylene blue may be a newer option for antidotal treatment of
vasodilatory shock from dihydropyridine overdoses, however the literature is limited to use in amlodipine overdoses
and no ideal doses of MB have been established.

Digoxin
Epidemiology
An estimated 4 to 5 percent of digoxin users per year experience toxicity.zs In 2011 alone, there were 2,513 reported
exposures to cardiac glycosides resulting in toxicity. The majority of cases were the result of an adverse event with prescribed use of a cardiac glycoside. Of the reported exposures,
the majority of cases were classified as being moderately
severe in nature, with 27 cases resulting in death.6 Each of
these incidents is estimated to have cost the U.S. health care
system between $1,500 and $6,500.25
Mechanism
Cardiac glycosides as a class exhibit their function by inhibiting the Na+/K+ ATPase in myocytes. Pump inhibition will
cause an increase in sodium concentration within the
ceJJ.26,27 This results in an increase in the resting membrane
potential of the myocyte, allowing voltage-gated calcium
channels to open and triggering calcium release from the
sarcoplasmic reticulum.26 Additionally, the Na+ /Ca2+ exchange pump will be affected by the change in sodium's electrochemical gradient, thus inhibiting its ability to drive
calcium from the cell. The overall increase in intracellular
calcium concentration results in positive inotropy. 27

In a toxic situation, the high sodium levels can cause phase IV
depolarization to lengthen and increase the resting membrane potential. This allows cardiac cells to fire off their own
action potential, and may lead to the development of arrhythmias.20
Presenting Symptoms of Toxicity
In addition to heart arrhythmias, toxic effects may be
observed in other organs throughout the body due to the
presence of Na+/K+ ATPase pumps in a multitude of cells.
Symptoms caused by digoxin toxicity include gastrointestinal
issues, such as nausea, vomiting, and anorexia, and neurological symptoms, including confusion, disorientation, lethargy, delirium, weakness, and vision disturbances.25,26,20
Chronic toxicity is typically observed in practice.6 These patients more frequently exhibit neurological symptoms than
those suffering from acute overexposure, who commonly
demonstrate the gastrointestinal side effects. In either situation, an ECG, may illustrate extrasystoles, ST depression, and
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minor degrees of AV node block, among other issues.20
Diagnosis and Treatment
It is important for pharmacists to be able to recognize and
properly treat patients that are exhibiting symptoms of digoxin toxicity, as treatment should be provided as soon as
possible. Although acute cases of toxicity may occur, in which
a patient may ingest excessive amounts of digoxin at one
time, most patients with digoxin toxicity experience chronic
·toxicity. In this instance, adverse events are exhibited after
multiple ingestions of the medication, during which the digoxin accumulates as a result of impaired drug clearance. As
such, there is a gradual increase in serum d.igoxin concentration until toxic levels are achieved. Thus, serum digoxin levels may be beneficial, but should be obtained after six hours
of ingestion to avoid misleading results in cases of acute ingestion.26 If the overdose is known to be acute and has occurred within two hours, cleansing the gastrointestinal system through the use of multiple doses of activated charcoal
may be a valid option.26,28 Gastric lavage should be utilized
with care, as it may worsen cases of bradycardia. Additionally, if a patient is experiencing hypokalemia, this condition
should be corrected.28

Treatment options for the patient's arrhythmia will be dependent upon how the patient is displaying, so this must be
treated on an individual basis.26 High levels of potassium will
hinder digoxin binding to the Na+/K+ ATPase, and therefore
may be useful in treating mild cases of overexposure.26,28 It
should also be noted that hyperkalemia can be problematic
to the patient's health, and should be monitored.28
First-line therapy, when available, is Digoxin-Fab. This medication is a highly utilized treatment method that functions as
a specific digoxin-binding antibody, thus decreasing the
amount of free digoxin to bind to the Na+/K+ ATPase.
Digoxin-Fab is indicated in both acute and chronic toxic
emergencies. 29 The onset of action is reported to occur in Jess
than 30 minutes. 29 A 40 mg vial of Digoxin-Fab will bind approximately 0.5 mg of ingested digoxin.25 Therefore, the
required dose of Digoxin-Fab is dictated by the amount of
consumed digoxin that must be nullified.28 Health care
professionals should remember that any time this drug is
utilized, there is the potential of developing a severe immunological reaction to the administered antibodies. Immune
responses to the antidote should be closely monitored.JO
In an acute crisis where an unknown amount of digoxin has
been ingested, 20 vials are typically sufficient for treatment.
They may be administered either all at once as a single dose
or divided into two equal doses. In the case of dividing into
two equal doses, one dose is administered and the patient's
response is monitored to determine if the other half is required.
In an acute situation in which the amount of consumed digoxin is known, the corresponding dose of Digoxin-Fab can
be calculated. Initially, the total body load of consumed digoxin should be determined using one of the following equations, depending upon the prepared formulation of digoxin:
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Once the value for total body load has been found, the number of vials of Digoxin-Fab that are necessary can be calculated as follows:

3.
4.

S.

6.

Digoxin-Fab required for treatment (mg)= Total body load
(mg) I o.s
Vials of Digoxin-Fab to be used = Digoxin-Fab required for
treatment (mg)/ 40 mg/vial
In this manner, the math can quickly be completed to determine the appropriate way to treat an overdose patient.29 The
pharmacist must utilize care in these situations, however,
due to the possibility of unreliable patient accounts regarding the amount of drug ingested.30

7.

8.

9.

10.

In a situation involving chronic overexposure, six vials is usually adequate to treat a patient.29
Calcium is typically contraindicated in patients suffering
from digoxin toxicity, because an excess of calcium can throw
the heart into a non-contractile state as a result of overstimulation. This is sometimes known as a "stone heart" state. Despite this, calcium is sometimes desired in the treatment
regimen to counteract the patient's hyperkalemia. In a recent
retrospective observational study conducted by Levine and
colleagues, patient outcomes were evaluated in cases of digoxin toxicity in which calcium treatment was utilized. Overall mortality between both those who received calcium and
those who did not were similar.27 These findings suggest that
calcium may not be harmful in digoxin overdose situations,
and that the health care practitioner must use professional
judgment when considering calcium as a treatment option to
combat hyperkalemia.
Supportive care should be provided for the patient in addition to one or more of the above treatment methods. This
will provide the patient with the best possible odds of surviving the digoxin overdose with minimal lasting effects.
Role for Pharmacists
Toxicity can be the result of acute or chronic exposure, and
may be either intentional or unintentional. In any scenario,
pharmacists play a vital role in the health care team by helping to select, properly dose and oversee drug treatments.
This becomes especially important in many of the previously
listed cases, in which treatment strategies may include multiple drugs and may require monitoring various parameters in
order to properly care for the patient.
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EmergencyMedicine - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - Assessment Questions

1.

Pronounced anticholinergic symptoms are common with
atypical antipsychotic toxicity. What intervention can be
used to manage these symptoms, especially agitated delirium?
A. Physostigmine
B. Edrophonium
c. Neostigmine
D. Pyridostigmine

7. In treating the sulfonylurea and meglitinide classes, it is
important to first give the patient
A. Normal saline solution continuous IV
8. Octreotide 50-100 mcg subcutaneously every
6-12 hours
C. Quickly metabolized carbohydrates in the form
of oral glucose or IV dextrose
D. Sodium bicarbonate 1-2 mEq/kg

2.

How is an atypical antipsychotic overdose primarily diagnosed?
A. By obtaining serum concentrations of the drug
8. Collecting and analyzing patient's clinical history, physical examination, and presenting
symptoms
C. Conducting urine screens
D. Monitoring changes in the ECG

8.

In the early stages of ___ toxicity, _ _ may be administered because of the medication's tendency to remain in the gastrointestinal tract.
A. Biguanide, Activated charcoal
B. Thiazolidinedione, Sodium bicarbonate
C. Thiazolidinedione, Octreotide
D. Biguanide, Octreotide

3. A patient suffering from an atypical antipsychotic overdose typically presents with symptoms involving what
system(s)?
A. Cardiovascular
B. Gastrointestinal
C. Central nervous system
D. A&C
E. All of the above

9.

JR, a 35-year-old male, arrives in the emergency room

4. What is the therapy of choice in treating beta-blocker
toxicity?
A. Atropine
B. Glucagon
C. Calcium
D. Catecholamines
5. What is unique about the presentation ofbiguanide toxicity compared to other oral hypoglycemics?
A. Elevated transaminases and alkaline phosphatase
B. Hypoglycemia
c. Lactic acidosis
D. No acute symptom onset
6. Thiazolidinediones do not present with acute symptoms
of toxicity because ...
A. They are considered to be a safer class of drugs
B. They have a very short tt;z
C. They have very low bioavailability upon oral
ingestion
D. They require the presence of insulin to exert
their effects

12

complaining of nausea and vomiting. It is determined
that he has acute digoxin toxicity. He states that he has
swallowed fifteen 25 mg tablets of digoxin. How many
vials of Digoxin-Fab will JR likely need for treatment?
A. 8 vials
B. 15 vials
C. 19 vials
D. 22 vials
10. What ion is associated with "stone heart" state in digoxin
toxicity?
A. Sodium
8. Potassium
C. Magnesium
D. Calcium

~.
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